Automated cell therapy development and manufacturing via robotic smart factories
Cellares runs automated cell therapy manufacturing out of smart factories, and its stack reads like an industrial automation shop: Beckhoff, Siemens and Allen-Bradley controllers, EPLAN and Altium for electrical design, Structured Text and C# for control code. MES, LIMS and SAP S/4HANA sit alongside this, which points to tightly regulated production operations. Current hiring is minimal and centers on electrical design for automation equipment.
Cellares is a privately held integrated development and manufacturing organization focused on cell therapies, founded in 2019 and headquartered in South San Francisco, California. It serves drug sponsors, helping them develop, scale and commercialize cell therapies using its automated platforms: Cell Shuttle for end-to-end manufacturing and Cell Q for automated quality control. The company operates smart factories in Bridgewater, New Jersey; Leiden, the Netherlands; and Kashiwa City, Japan. It employs 201–500 people.
Cellares uses Beckhoff, Siemens and Allen-Bradley automation hardware, EPLAN and Altium Designer for electrical design, Python, C# and Structured Text, plus MES, LIMS, SAP S/4HANA, Snowflake, Power BI and Salesforce.
Cellares is headquartered in South San Francisco, California, and operates smart factories in Bridgewater, New Jersey; Leiden, the Netherlands; and Kashiwa City, Japan.
Hiring is currently minimal and limited to the United States. The open work is in engineering and manufacturing, focused on electrical design for automation equipment and prototyping test benches.
Other companies in the same industry, closest in size
Cellares's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.